Sidoti Csr Comments on Balchem’s Q1 Earnings (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Sidoti Csr increased their Q1 2025 earnings per share estimates for Balchem in a research note issued to investors on Tuesday, February 25th. Sidoti Csr analyst D. Harriman now anticipates that the basic materials company will post earnings per share of $1.25 for the quarter, up from their prior forecast of $1.19. The consensus estimate for Balchem’s current full-year earnings is $4.64 per share. Sidoti Csr also issued estimates for Balchem’s Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.30 EPS, Q4 2025 earnings at $1.27 EPS, FY2025 earnings at $5.10 EPS, Q1 2026 earnings at $1.33 EPS, Q2 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.38 EPS, Q4 2026 earnings at $1.33 EPS and FY2026 earnings at $5.40 EPS.

Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.11 by ($0.08). The firm had revenue of $240.00 million during the quarter, compared to the consensus estimate of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%.

Several other analysts have also commented on the company. HC Wainwright reiterated a “buy” rating and set a $190.00 price objective on shares of Balchem in a report on Monday. StockNews.com cut shares of Balchem from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Sidoti upgraded shares of Balchem to a “hold” rating in a research note on Tuesday.

Balchem Price Performance

Shares of BCPC opened at $172.00 on Wednesday. The company has a 50 day moving average of $162.24 and a two-hundred day moving average of $169.48. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. Balchem has a twelve month low of $137.69 and a twelve month high of $186.03. The company has a market cap of $5.60 billion, a price-to-earnings ratio of 43.77, a price-to-earnings-growth ratio of 4.41 and a beta of 0.69.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. FMR LLC increased its holdings in Balchem by 944.3% in the 3rd quarter. FMR LLC now owns 497,495 shares of the basic materials company’s stock worth $87,559,000 after buying an additional 449,854 shares during the period. Norges Bank purchased a new position in shares of Balchem during the fourth quarter worth $70,165,000. Proficio Capital Partners LLC purchased a new position in shares of Balchem during the fourth quarter worth $23,628,000. Bank of America Corp DE lifted its position in Balchem by 120.9% during the fourth quarter. Bank of America Corp DE now owns 156,562 shares of the basic materials company’s stock valued at $25,519,000 after purchasing an additional 85,692 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Balchem in the fourth quarter valued at $13,359,000. 87.91% of the stock is currently owned by hedge funds and other institutional investors.

Balchem Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Friday, January 17th. Stockholders of record on Thursday, December 26th were issued a $0.87 dividend. The ex-dividend date was Thursday, December 26th. This is a positive change from Balchem’s previous annual dividend of $0.79. This represents a dividend yield of 0.4%. Balchem’s dividend payout ratio is currently 22.14%.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.